ISC 2026 | Paradigm shift in chronic subdural hematoma management driven by EMMA

We are witnessing a genuine paradigm shift in how chronic subdural hematoma is managed, and it’s being driven by EMMA, as we call it, embolization of middle meningeal artery. For decades, the standard treatment for chronic subdural hematoma was straightforward, surgically drained, the blood collection. While surgery is effective in the early phase or short term, recurrence rates have remained frustratingly high, 20 to 30 percent, as I said earlier, because surgery removes the blood but does not address the underlying disease process. We now understand that chronic subdural hematoma is not simply a static bleed. It’s a dynamic inflammatory condition sustained by the fragile abnormal blood vessels in the subdural membrane. These vessels are largely supplied by the middle meningeal artery. Embolization targets the root cause. By blocking that arterial supply, we interrupt the cycle of inflammation, membrane formation, and re-bleeding. Rather than just evacuating the hematoma, we are kind of biologically modifying the disease. High-quality randomized trials, including our own EMMA-Can trial, have demonstrated that adding embolization to surgery significantly reduces recurrence. This has shifted thinking from drain and wait to a more durable mechanism-based approach. And in some centers, embolization is even being explored as a primary therapy in selected patients. The broader implication is substantial. Chronic subdural hematoma primarily affects older adults, often frail patients, and many of these are on blood thinners. Reducing recurrence means fewer repeat surgeries, fewer hospital readmissions, and potentially safer care. It also opens the door to less invasive, potentially anesthesia-sparing strategies, which is particularly important in elderly patients. So the paradigm shift is twofold. Scientifically, we now treat chronic subdural hematoma as a vascular inflammatory disease rather than simply a surgical problem. Clinically, we are moving towards integrated, minimally invasive strategies that aim to prevent recurrence rather than just manage it. The evolution represents one of the most significant advances in neurosurgical care for older adults in decades, honestly speaking.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.